* "Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells", Shojaei F., Wu X., Baldwin ME., Zhong C., Malik A., Shanz S., Fuh G., Gerber HP., Ferrara N., Nature Biotechnology, 2007